Results 21 to 30 of about 1,247,370 (242)

Clinical trials in oncology

Medicine, 2008
The development of a new treatment in cancer generally involves its assessment in Phase I, II and III prospective clinical trials. This article gives an overview of these phases of clinical trial, through which almost every new treatment will need to pass on the journey from its discovery on the laboratory bench to its routine use in clinical practice.
openaire   +6 more sources

Glucocorticoids in clinical oncology

Cleveland Clinic Journal of Medicine, 1992
Glucocorticoids have been used in clinical oncology for more than three decades. Their anti-inflammatory action plays a major role in their clinical applications in oncology. The incidence and severity of side effects depend on the total dose and the duration of therapy, but optimal dosages for these drugs have not been determined.
Declan Walsh, Jay Avashia
openaire   +3 more sources

Clinical trials in oncology [PDF]

, 2018
Klinične raziskave ali klinična preskušanja so raziskave, ki vključujejo ljudi. Na njihovih izsledkih temelji vsakodnevna obravnava bolnikov, zdravljenje, ki temelji na dokazih. Klinična preskušanja razvrščamo v več faz.
Matos, Erika
core   +2 more sources

American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology [PDF]

Journal of Oncology Practice, 2016
The use of clinical pathways in oncology care is increasingly important to patients and oncology providers as a tool for enhancing both quality and value. However, with increasing adoption of pathways into oncology practice, concerns have been raised by ASCO members and other stakeholders.
Dana S. Wollins, James N. Frame, Linda D. Bosserman, Steven K. Stranne, Robin Zon, Michael N. Neuss, Ray D. Page   +6 more
openaire   +3 more sources

Patient-centric trials for therapeutic development in precision oncology [PDF]

, 2015
An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours.
A Hollebecque, A-M Tsimberidou, AD Barker, AL Tam, Andrew V. Biankin, AT Shaw, AV Biankin, B Zhang, C Le Tourneau, C Le Tourneau, C Lin, C Printz, CK Lee, CR Lindsay, D Cook, D Slamon, D Zardavas, DD Von Hoff, DE Gerber, DJ Sargent, DT Le, EA Eisenhauer, ED Green, ES Kim, F André, GD Demetri, GM Frampton, IR Watson, J Ledermann, J Lewin, J Verweij, JA Sosman, JY Douillard, L Chin, L Chin, L Seguin, LA Chantrill, LB Alexandrov, LJ Esserman, LJ Esserman, M Hay, M Maemondo, MG Kris, MR Stratton, MR Stratton, N Roper, N Waddell, NM Hylton, PA Jänne, PN Lara Jr, R Dienstmann, R Simon, RR Kalf, S Matsumoto, S Sleijfer, Simon J. Hollingsworth, SJ Dawson, SJ Mandrekar, Steven Piantadosi, TA Yap, TJ Hudson   +60 more
core   +1 more source

BRAF inhibitors in clinical oncology [PDF]

F1000Prime Reports, 2013
Activating mutations of the BRAF oncogene are present in approximately 5-10% of all human malignancies and lead to constitutive activation of the mitogen activated protein kinase (MAPK) pathway. The introduction of BRAF inhibitors has greatly improved the short term prospects of some patients with these tumors, but the tumors tend to become resistant ...
Van K. Morris, Scott Kopetz
openaire   +3 more sources

The Sir Anthony Mamo Oncology Centre [PDF]

, 2015
In 2009, the development of a medical brief, effectively detailing the specifications for a purpose-built oncology hospital and including the medical equipment and human resources required, was commenced. Robust engagement by the relevant stakeholders,
Laspina, Stefan
core  

B cell mechanobiology in health and disease: emerging techniques and insights into therapeutic responses

FEBS Letters, EarlyView.
B cells sense external mechanical forces and convert them into biochemical signals through mechanotransduction. Understanding how malignant B cells respond to physical stimuli represents a groundbreaking area of research. This review examines the key mechano‐related molecules and pathways in B lymphocytes, highlights the most relevant techniques to ...
Marta Sampietro, Marco Cellani, Cristina Scielzo   +2 more
wiley   +1 more source

Letter. Intensity-modulated radiotherapy for the treatment of breast cancer [PDF]

, 2013
In the systematic review of intensity-modulated radiotherapy (IMRT) in the treatment of breast cancer reported in Clinical Oncology by Dayes and colleagues [1], the only prospective randomised clinical trial (n = 306) testing forward-planned IMRT to have
Coles, C.E., Donovan, E., Haviland, J.S., Yarnold, J.   +3 more
core   +1 more source

Flow‐based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product

Molecular Oncology, EarlyView.
The number of circulating tumor cells obtained from prostate cancer patients was increased approximately 5‐fold compared to regular CellSearch when processing 2 mL diagnostic leukapheresis material aliquots and increased by 44‐fold when processing 20 mL DLA aliquots using the flow enrichment target capture Halbach‐array.
Michiel Stevens, Anouk Mentink, Frank A. W. Coumans, Eshwari Dathathri, Khrystany T. Isebia, Jaco Kraan, Ronald de Wit, John W. M. Martens, Leon W. M. M. Terstappen   +8 more
wiley   +1 more source